Biopharma giant Johnson & Johnson’s ($JNJ) stock hit new highs this year after reporting its Q2 results on July 16th, giving ...

Having a respected veteran like Byard buying into Johnson's philosophy, it's a big sign of leadership for this franchise.

Johnson & Johnson's stock offers value with promising MedTech growth, raised guidance, strong dividends, and bullish ...